Ben Mauro's Sci-Fi Epic 'HUXLEY' Launches Globally with Hardcover & Softcover Editions; New Trailer and Prequel 'The Oracle' Announced for October Release
11.6.2025 15:00:00 EEST | Business Wire | Press release
Renowned concept artist and storyteller Ben Mauro, known for his work on major franchises such as Halo Infinite, Call of Duty, and Elysium, proudly announces the worldwide release of his acclaimed sci-fi graphic novel series, HUXLEY. The series is now available in hardcover and softcover editions through major retailers, including Amazon and bookstores globally.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250610972522/en/
Screenshot from HUXLEY: THE ORACLE.
Set in the post-apocalyptic world of FURY-7, HUXLEY follows the journey of Max, a seasoned Ronin warrior, and his companions as they navigate a landscape dominated by ancient machines and rogue AI empires. The narrative combines cinematic world-building with mythic storytelling, appealing to fans of Dune, Ghost in the Shell, and Warhammer 40K.
In conjunction with the book launch, a new trailer has been released for the upcoming prequel, HUXLEY: The Oracle, offering a glimpse into the origins of the saga. The prequel, set to release in October 2025, delves deeper into the lore of the HUXLEY universe, exploring the rise of the Oracles—the enigmatic machine rulers of the wasteland—and the early days of the AI wars.
HUXLEY Oracle Trailer
https://www.youtube.com/watch?v=7nbOCqbkUA4
HUXLEY Hardcover
https://vol.co/collections/huxley
https://vol.co/collections/the-oracle
HUXLEY Softcover
https://www.thamesandhudsonusa.com/books/huxley-softcover
https://www.amazon.com/HUXLEY-Ben-Mauro
Ben Mauro's vision for HUXLEY extends beyond the pages of the graphic novel, encompassing a transmedia approach that includes games, animation, and collectibles. The franchise has garnered significant attention, with its cinematic teaser amassing over 3.6 million views on YouTube and a growing global fanbase.
“HUXLEY is the universe I’ve always dreamed of creating,” says Mauro. “It's a homage to the inspirations of my youth, reimagined for a new generation.”
HUXLEY is available now via Amazon and major retailers. For more information, updates, and to watch the new trailer, visit www.huxleysaga.com.
About HUXLEY
HUXLEY is a post-apocalyptic sci-fi universe set in the far future, where ancient machines, rogue AIs, and forgotten empires shape the fate of humanity. Spanning graphic novels, cinematic trailers, and future game and animation projects, HUXLEY blends mythic storytelling with AAA-level worldbuilding. With a rapidly growing global fanbase, it offers a rich transmedia experience designed for readers, gamers, and collectors alike.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250610972522/en/
Contacts
Media Contact:
Ben Mauro
Benmauro@huxleysaga.com
www.huxleysaga.com -
https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.huxleysaga.
com&esheet=54270340&newsitemid=20250610972522&lan=en-US&anchor=www.huxleysaga.co
m&index=7&md5=121a8a1406bc40ad55c88612c9e76903
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
www.businesswire.com
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 20:52:00 EEST | Press release
International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he has served as pro bono counsel to five Nobel Peace Prize laureates. The New York Times has referred to him as "The Extractor" for his work freeing political prisoners worldwide. Genser's decision to support Yim Leak's team comes as the businessman faces an asset freeze exceeding 20 billion baht (more than U
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 18:38:00 EEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 15:00:00 EEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu ® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DES
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 13:58:00 EEST | Press release
Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom